Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available athttp://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com


                              Keryx Biopharmaceuticals, Inc.
                           Selected Consolidated Financial Data
                    (In Thousands, Except Share and Per Share Amounts)

    Statements of Operations Information:

                                   Three Months Ended     Six Months Ended
                                        June 30,               June 30,
                                      (unaudited)            (unaudited)
                                    2009       2008        2009       2008


    REVENUE:
    License revenue            $  18,289     $  327   $  21,616     $  526
    Service revenue                   --         62           3         62
    Other reven
'/>"/>
SOURCE  Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 Envera announced ... Fermentation Manager. Mr. McErlean has an extensive background ... leadership positions throughout his career. , Mike ... very pleased to have Mike join our team”. “Mike’s ... large scale fermentation and downstream processing equipment”, ...
(Date:5/21/2013)... WEST PALM BEACH, Fla. , May 21, ... Inc. (NYSE: FCN ), the global ... and enhance their enterprise value (the "Company"), announced ... sciences focused personnel that were formerly included within ... Forensic and Litigation Consulting segment to form a ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... According to a new market ... "Biochip Products and Services Market (Microarrays, Reagents, Drug Discovery, ... Share, Growth, Trends and Forecast, 2012 - 2018," the market was valued ... to grow at a CAGR of 10.1% from 2012 ... 4.7 billion in 2018. Browse the full ...
Breaking Biology Technology:Envera Appoints Michael McErlean Fermentation Manager 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5
... Ortho Biotech is pleased,with recommendations of ... Renal Drugs Advisory Committee (CRDAC) and Drug ... from the,Committees, evaluation of the use of ... failure (CRF). "Ortho Biotech supports the ...
... 11 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... Marcial of BusinessWeek, highlighted Access Pharmaceuticals in ... The article is also available,on http://www.BusinessWeek.com ... The article focused upon the major ...
... Additional Phase 3 Trials on Track for Initiation Later ... for Today at 8:30 a.m. Eastern Time -, ... ARNA ) announced today that an independent Echocardiographic,Data Safety ... to stop,the ongoing pivotal Phase 3 trial, BLOOM (Behavioral ...
Cached Biology Technology:Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 2Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 3Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 4Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients 5Access Highlighted in Recent BusinessWeek Article 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 6
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Drugs found to both prevent and treat Alzheimer's disease in mice 2
... Institute is home to a rich trove of biological ... genetic Library of Congressholds over 147,000 plasmids, (circular DNA ... as well as full genome collections from numerous organisms ... A new $6.5 million grant from the National ...
... its initial appearance in New York in 1999, West Nile ... years and is now well established throughout North and South ... birds that are important hosts for the virus are abundant ... As a result, transmission of West Nile virus is highest ...
... (NSF) has awarded $3 million to Clemson University to ... sensors to monitor water quality along the entire length ... represents a ,big idea, worthy of Thomas Green Clemson, ... scientific research and education," said Clemson President James F. ...
Cached Biology News:Clearing house for DNA gets a boost 2Clearing house for DNA gets a boost 3West Nile virus transmission linked with land-use patterns and 'super-spreaders' 2West Nile virus transmission linked with land-use patterns and 'super-spreaders' 3Clemson's Intelligent River technology to provide real-time monitoring of river 2Clemson's Intelligent River technology to provide real-time monitoring of river 3Clemson's Intelligent River technology to provide real-time monitoring of river 4
Black Polypropylene 384 Round Well Plate 70/Box...
... • Heat activated ,• ... room temperature ,• Excellent specificity allows ... and secondary structures ,• Leaves an ... chemically modified form of GeneChoice DNA Polymerase ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
... BioControl multichannel has the ... the single channel model.The ... allseven multichannel and five ... modules. Both pipettes have ...
Biology Products: